FDA Determines Regulatory Review Period for AUBAGIO Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of AUBAGIO, a human drug product, following a submission to the US Patent and Trademark Office (USPTO). This decision was made in accordance with federal regulations.